Clinical Research Study — Now Enrolling
R.E.M.S. uses radiofrequency ultrasound — no ionizing radiation. Selected participants receive a full bone health assessment at no cost as part of our clinical research protocol.
Discover MoreEvery participant receives a detailed bone health report. Your data — fully anonymized — contributes to a growing body of evidence comparing R.E.M.S. and DEXA outcomes.
Contact UsFewer than half of Americans at risk for osteoporosis ever get tested. Participants are selected from known patient populations. If you have been contacted by BoneVue, your participation directly contributes to this important research.
The TechnologyThe Research
DEXA has been the standard for measuring bone density for decades — but it uses radiation, requires specialized facilities, and insurance rarely covers it before age 65.
R.E.M.S. technology, developed in Italy and FDA-cleared in the United States in 2024, offers a radiation-free alternative that may be more accessible and equally accurate.
BoneVue is conducting a clinical study to gather the comparative data that clinicians need to adopt it widely. Your participation matters.
How to ParticipateTechnology
R.E.M.S. — Radiofrequency Echographic Multi Spectrometry — was developed in Italy by Echolight and launched in the EU in 2017. It measures bone mineral density and microarchitecture using radiofrequency ultrasound signals, producing results comparable to DEXA without any radiation exposure.
In 2018, Osteoporosis International published results from a multicenter clinical trial comparing R.E.M.S. and DEXA for diagnosing osteoporosis at the lumbar spine and femoral neck. The findings were strong enough that the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) issued a consensus statement in 2019 highlighting R.E.M.S. as a meaningful advancement in bone imaging.
In 2024, R.E.M.S. technology received FDA clearance in the United States. BoneVue's clinical study builds on this international evidence base with U.S. population data.
Contact Us| Feature | R.E.M.S. | DEXA |
|---|---|---|
| Radiation | None | Ionizing |
| Measures BMD | Yes | Yes |
| Bone quality | Yes | Limited |
| Portable | Yes | Fixed facility |
| FDA cleared (US) | 2024 | Decades |
| Insurance coverage | Study only | Usually 65+ |
Eligibility
Our study draws participants from several groups known to be at elevated risk for bone density loss:
Bone loss can begin during perimenopause and accelerates during and after menopause. Early assessment is key.
The risk of stress fractures due to diminished bone density in this group is well-documented in medical literature.
A woman's risk of an osteoporotic hip fracture equals her combined risk of breast, uterine and ovarian cancer. Each year, 80,000 men fracture a hip.
Certain conditions accelerate bone loss: diabetes, cancer, nutritional deficiencies, chronic prednisone use, and anti-seizure medications.
Why R.E.M.S.
Until recently, DXA (DEXA) was the only clinically-validated tool to measure bone density and the risk for osteoporosis. While DEXA has been incredibly important, clinicians agree it is not perfect.
DEXA uses ionizing radiation and can provide inconsistent results. It is generally not sensitive enough to detect changes more frequently than every two years, and certain underlying conditions can mask true bone health. Insurance typically does not cover it before age 65.
R.E.M.S. technology launched in the EU in 2017 and has been expanding globally. In 2018, Osteoporosis International published a pivotal multicenter trial comparing R.E.M.S. and DEXA. In 2019 ESCEO released a consensus paper highlighting R.E.M.S. as advancing bone health imaging. In 2024, R.E.M.S. became commercially available in the United States as an FDA-cleared diagnostic imaging device.
BoneVue is now conducting clinical research to document comparative outcomes in the U.S. population — and you can be part of it.
Interested in participating in the study, or want to learn more about R.E.M.S. technology? Reach out to the BoneVue team.